Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon

Shantibhusan Senapati, Samuel B. Ho, Poonam Sharma, Srustidhar Das, Subhankar Chakraborty, Sukwinder Kaur, Gloria Niehans, Surinder Kumar Batra

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aim: To determine the cellular location and expression of MUC17 mucin in specimens of normal, inflamed and neoplastic colon. Methods: Immunohistochemical analysis of human surgical resection specimens (n=106) was performed with a specific antibody to the MUC17 apomucin protein. A semi-quantitative scoring system was used to measure MUC17 expression. In various colon cancer cell lines, the MUC17 expression was examined by immunoblot analysis and normal RT-PCR. Results: MUC17 was highly expressed on the surface epithelium and crypts of colonic mucosa. In contrast, the expression of MUC17 was significantly decreased in colonic mucosa of chronic ulcerative colitis (p<0.0001) and ischaemic colitis (p=0.003). Similarly, MUC17 expression was decreased in hyperplastic polyps (p=0.0003), tubular and tubulovillous adenomas (p<0.0001) and colon cancers (p<0.0001). Furthermore, of eight different colon cancer cell lines, MUC17 expression was only detected in LS174T and LS180 cells. Conclusion: Results indicate that the potential protective effects of this membrane-bound mucin are primarily or secondarily diminished in inflammatory and neoplastic conditions. Further research is needed to determine the specific role of MUC17 in the pathogenesis of these conditions.

Original languageEnglish (US)
Pages (from-to)702-707
Number of pages6
JournalJournal of Clinical Pathology
Volume63
Issue number8
DOIs
StatePublished - Aug 1 2010

Fingerprint

Mucins
Colonic Neoplasms
Colon
Membranes
Mucous Membrane
Ischemic Colitis
Cell Line
Polyps
Ulcerative Colitis
Adenoma
Epithelium
Polymerase Chain Reaction
Antibodies
Research
Proteins

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon. / Senapati, Shantibhusan; Ho, Samuel B.; Sharma, Poonam; Das, Srustidhar; Chakraborty, Subhankar; Kaur, Sukwinder; Niehans, Gloria; Batra, Surinder Kumar.

In: Journal of Clinical Pathology, Vol. 63, No. 8, 01.08.2010, p. 702-707.

Research output: Contribution to journalArticle

Senapati, Shantibhusan ; Ho, Samuel B. ; Sharma, Poonam ; Das, Srustidhar ; Chakraborty, Subhankar ; Kaur, Sukwinder ; Niehans, Gloria ; Batra, Surinder Kumar. / Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon. In: Journal of Clinical Pathology. 2010 ; Vol. 63, No. 8. pp. 702-707.
@article{dff0f8a05bc54b4cb7be95a22f9f9632,
title = "Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon",
abstract = "Aim: To determine the cellular location and expression of MUC17 mucin in specimens of normal, inflamed and neoplastic colon. Methods: Immunohistochemical analysis of human surgical resection specimens (n=106) was performed with a specific antibody to the MUC17 apomucin protein. A semi-quantitative scoring system was used to measure MUC17 expression. In various colon cancer cell lines, the MUC17 expression was examined by immunoblot analysis and normal RT-PCR. Results: MUC17 was highly expressed on the surface epithelium and crypts of colonic mucosa. In contrast, the expression of MUC17 was significantly decreased in colonic mucosa of chronic ulcerative colitis (p<0.0001) and ischaemic colitis (p=0.003). Similarly, MUC17 expression was decreased in hyperplastic polyps (p=0.0003), tubular and tubulovillous adenomas (p<0.0001) and colon cancers (p<0.0001). Furthermore, of eight different colon cancer cell lines, MUC17 expression was only detected in LS174T and LS180 cells. Conclusion: Results indicate that the potential protective effects of this membrane-bound mucin are primarily or secondarily diminished in inflammatory and neoplastic conditions. Further research is needed to determine the specific role of MUC17 in the pathogenesis of these conditions.",
author = "Shantibhusan Senapati and Ho, {Samuel B.} and Poonam Sharma and Srustidhar Das and Subhankar Chakraborty and Sukwinder Kaur and Gloria Niehans and Batra, {Surinder Kumar}",
year = "2010",
month = "8",
day = "1",
doi = "10.1136/jcp.2010.078717",
language = "English (US)",
volume = "63",
pages = "702--707",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon

AU - Senapati, Shantibhusan

AU - Ho, Samuel B.

AU - Sharma, Poonam

AU - Das, Srustidhar

AU - Chakraborty, Subhankar

AU - Kaur, Sukwinder

AU - Niehans, Gloria

AU - Batra, Surinder Kumar

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Aim: To determine the cellular location and expression of MUC17 mucin in specimens of normal, inflamed and neoplastic colon. Methods: Immunohistochemical analysis of human surgical resection specimens (n=106) was performed with a specific antibody to the MUC17 apomucin protein. A semi-quantitative scoring system was used to measure MUC17 expression. In various colon cancer cell lines, the MUC17 expression was examined by immunoblot analysis and normal RT-PCR. Results: MUC17 was highly expressed on the surface epithelium and crypts of colonic mucosa. In contrast, the expression of MUC17 was significantly decreased in colonic mucosa of chronic ulcerative colitis (p<0.0001) and ischaemic colitis (p=0.003). Similarly, MUC17 expression was decreased in hyperplastic polyps (p=0.0003), tubular and tubulovillous adenomas (p<0.0001) and colon cancers (p<0.0001). Furthermore, of eight different colon cancer cell lines, MUC17 expression was only detected in LS174T and LS180 cells. Conclusion: Results indicate that the potential protective effects of this membrane-bound mucin are primarily or secondarily diminished in inflammatory and neoplastic conditions. Further research is needed to determine the specific role of MUC17 in the pathogenesis of these conditions.

AB - Aim: To determine the cellular location and expression of MUC17 mucin in specimens of normal, inflamed and neoplastic colon. Methods: Immunohistochemical analysis of human surgical resection specimens (n=106) was performed with a specific antibody to the MUC17 apomucin protein. A semi-quantitative scoring system was used to measure MUC17 expression. In various colon cancer cell lines, the MUC17 expression was examined by immunoblot analysis and normal RT-PCR. Results: MUC17 was highly expressed on the surface epithelium and crypts of colonic mucosa. In contrast, the expression of MUC17 was significantly decreased in colonic mucosa of chronic ulcerative colitis (p<0.0001) and ischaemic colitis (p=0.003). Similarly, MUC17 expression was decreased in hyperplastic polyps (p=0.0003), tubular and tubulovillous adenomas (p<0.0001) and colon cancers (p<0.0001). Furthermore, of eight different colon cancer cell lines, MUC17 expression was only detected in LS174T and LS180 cells. Conclusion: Results indicate that the potential protective effects of this membrane-bound mucin are primarily or secondarily diminished in inflammatory and neoplastic conditions. Further research is needed to determine the specific role of MUC17 in the pathogenesis of these conditions.

UR - http://www.scopus.com/inward/record.url?scp=77955722731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955722731&partnerID=8YFLogxK

U2 - 10.1136/jcp.2010.078717

DO - 10.1136/jcp.2010.078717

M3 - Article

VL - 63

SP - 702

EP - 707

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 8

ER -